FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 17, 2025

The coronavirus disease 2019 (COVID-19) pandemic has devastated global health and the economy, underscoring urgent need for extensive research into mechanisms of severe acute respiratory syndrome 2 (SARS-CoV-2) viral entry development effective therapeutic interventions. We established a cell line expressing human angiotensin-converting enzyme (ACE2). used it as model pseudotyped using murine leukemia virus (MLV) SARS-CoV-2 spike (S) protein on its surface firefly luciferase reporter. screened an U.S. Food Drug Administration (FDA)-approved compound library inhibiting ACE2-dependent identified several drug-repurposing candidates. 18 drugs drug candidates, including 14 previously reported inhibitors four novel Pyridoxal 5'-phosphate, Dovitinib, Adefovir dipivoxil, Biapenem potently inhibit with inhibitory concentration 50% (IC50) values 57nM, 74 nM, 130 183 respectively. FDA-approved candidate anti-SARS-CoV-2 combination therapy. Our findings contribute to growing body evidence supporting repurposing viable strategy rapidly developing COVID-19 treatments.

Язык: Английский

Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation, 2nd Edition

Viruses, Год журнала: 2025, Номер 17(5), С. 601 - 601

Опубликована: Апрель 23, 2025

After the success of Special Issue entitled “Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation” (https://www [...]

Язык: Английский